homepage  accelmed vision  strategy  team  portfolio  contact    accelmed invests in private and public medical device companies around the world accelmed merges global businesses with promising medical device startups creating significant revenue growth accelmed’s platform model has proven to provide high returns to investors managers and entrepreneurs accelmed invests in private and public medical device companies around the world accelmed merges global businesses with promising medical device startups creating significant revenue growth accelmed’s platform model has proven to provide high returns to investors managers and entrepreneurs accelmed invests in private and public medical device companies around the world accelmed merges global businesses with promising medical device startups creating significant revenue growth accelmed’s platform model has proven to provide high returns to investors managers and entrepreneurs             merging medtech innovation with global commercial platforms    accelmed is an investment firm focused on value creation for medical device companies and technologies accelmed was founded in  by mori arkin and uri geiger and invests in small and midcap private and public companies with its proven track record and large team of accomplished investment professionals accelmed’s vision is to create leading medtech players by merging commercial platforms with small innovative growth companies predominantly from israel                       integrating commercial platforms with innovation and providing growth equity to foster significant value creation   accelmed brings its acumen in medical devices and its dominant presence in israel to the platform model which has already been implemented with great success under the platform model accelmed integrates innovative and marketready medical device technologies into existing commercial companies that are able to effectively distribute and commercialize the new products accelmed makes significant equity investments – or a combination of equity and debt – of between m and m per platform in certain cases in combination with its coinvesting partners investment can be increased to up to m we intend to acquire a significant interest in established medical device companies in the us europe and potentially in china with revenues in excess of m and which have an experienced direct sales force     proceeds of our investments will be used for both organic and inorganic growth through the acquisition and integration of innovative market ready medical device technologies identified and selected by accelmed and the platform company management the acquired israeli startups will serve as ongoing sources for costefficient rd as based on accelmed’s proven experience with israeli rd teams  they are not only innovative but also operate in a faster and more efficient way than their peers overseas     platform case studies endochoice – platform model case study the platform model modus operandi is best illustrated through the merger between peer medical an israeli company and developer of the full spectrum endoscope and endochoice a gastroenterology gi player in atlanta ga which had a solid commercial infrastructure but which lacked innovative products by merging peer into endochoice and the addition of working capital accelmed was able to transform endochoice from a commodity player into a cutting edge technology company the merger carried out in  led to endochoice’s emergence as a leading global gi player with sales above m in  more than doubled since the merger high doubledigit growth and a presence in more than  countries endochoice completed a successful ipo on june  and was sold to boston scientific in october          ois – platform model case study ois is another example of the successful deployment of accelmed’s platform model ois a californiabased ophthalmic imaging systems player acquired medivision the developer of an innovative retinal camera based on israeli defense technology the deal was financed and led by accelmed which held  of ois’s shares postmerger in  within two years ois was sold providing accelmed with an outstanding return                       team  mori arkin cofounder and chairman of the investment committee   mori arkin is one of israel’s most successful life science entrepreneurs he was the principal shareholder and chairman of agis industries  ltd from its establishment until its merger with perrigo in 0 agis one of the leading generic pharmaceutical companies in israel merged with usbased perrigo in march 0 in an  million transaction mr arkin has a degree in psychology and philosophy from the tel aviv university  dr uri geiger cofounder and managing partner   uri geiger brings extensive entrepreneurial management and investment knowhow having created and built many successful medical device enterprises until january  dr geiger served as ceo of exalenz bioscience ltd taseexen developer of an innovative breathbased technology for diagnosing liver and gastrointestinal disorders that was acquired from oridion systems today part of covidien and dr geiger took public in 0 he previously cofounded and was the ceo of galayor networks a developer of optical components sold in 0 to memscap euronext mems dr geiger is also the founding partner of dragon variation fund one of israel’s first hedge funds which was sold to migdal in 0 dr geiger worked on wall street during the s where he gained a broad understanding of capital markets and significant experience which he put to use after returning to israel in  dr geiger was formerly an adjunct professor at the recanati business school at tel aviv university where he lectured on private equity and venture capital he is the author of the books startup companies and venture capital tel aviv university press 0 and from concept to wall street financial times – prentice hall 0 he earned his doctorate from new york’s columbia university center for law  economics where he majored in global equity markets dr geiger served as a major in the israeli air force  dr irit yaniv md mba general partner   irit yaniv is an experienced and accomplished senior executive in the medtech industry and has held ceo positions with medical device companies impulse dynamics and metacure she plays an important role in leading accelmed’s early stage portfolio companies serving either as chairperson or as an active board member dr yaniv holds an md degree from the bengurion university and an mba from the recanati business school at tel aviv university  ilan ben oren partner  cto   mr ben oren brings more than  years’ experience in rd and management in the medical equipment field  mr ben oren assists accelmed’s portfolio companies in various development tasks prior to joining accelmed he served as the cto of exalenz bioscience ltd taseexen a developer of an innovative breathbased technology for diagnosing liver and gastrointestinal disorders prior to that mr ben oren held various positions from project manager to cto at oridion medical swxoridn earlier in his career he worked as a senior physicist at scitex ltd nasdaqscix and participated for five years in applied research at the laser center of hadassah hospital einkerem and the hebrew university mr ben oren is the author of more than  patents and patent applications in the field of medical technologies and electrooptics he holds a master’s degree in applied physics and the science of materials summa cum laude from the hebrew university of jerusalem  amir blatt partner   amir blatt brings wide experience in both the investment and medical device fields prior to joining accelmed mr blatt was an analyst at goren capital group advising investors ta companies and the government of israel on ma activity previously mr blatt held several sales and marketing positions with dover medical devices the jj distributor of diagnostics equipment in israel mr blatt graduated as a biotechnology engineer from the technionisrael institute of technology in haifa and holds an mba from the recanati school of management at tel aviv university  dr guy ohad chief medical officer   dr guy ohad is a radiologist with rich experience in the field of technology and medical devices his most recent positions include ceo at pop medical solutions a woman’s health company developing a minimal invasive device for treatment of pelvic organ prolapse before this he was vp of clinical and business development of the cr product line at orex a csh company former kodak in addition he served as a consultant to several medical device companies and served as clinical advisor at medica vc dr ohad holds a md from tel aviv university  dr susan alpert md phd chief regulatory officer   susan alpert formerly chief regulatory officer of medtronic is accelmed’s senior regulatory and clinical advisor she provides services to accelmed on a part time  basis working with accelmed portfolio companies as well as assisting accelmed in reviewing and evaluating investment opportunities dr alpert has held the positions of senior vice president and chief regulatory officer at medtronic until  and had a similar role at cr bard nysebcr before joining medtronic she held a number of positions with the fda including as director of the fda’s office of device evaluation dr alpert holds md and phd in infectious diseases from the nyc school of medicine   nadav shimoni associate   madav shimoni completed his medical studies at the ben gurion university bgu of the negev in beer sheva mr shimoni previously served as a project manager at an idf elite technological unit gaining significant experience in developing and designing complex mechanical elements in addition he is an anatomy teaching assistant at the medical school for international health msih – a collaboration between bgu and columbia university medical center he also engages in active volunteering work including medical workshops for populations in need  nir gilad analyst   nir gilad is involved with investment analysis and ongoing portfolio management prior to accelmed mr gilad worked at the israeli ministry of defense as a project finance analyst leading the national project of relocating the idf’s units to the south of israel previously he served as a financial analyst at the idf’s elite technology unit leading the unit’s economic analysis awarded with an honor for excellence mr gilad is an associate mentor at the global business studies program at coller school of management at tel aviv university and he holds a ba in economics and an mba both from tel aviv university  dr gilad rotem analyst   dr rotem holds an md degree from the technionisrael institute of technology in haifa israel as well as a bsc from tel aviv university in industrial engineering and another in biology in addition mr rotem was formerly professional longdistance triathlete who has participated in numerous international competitions mr rotem’s strong academic background and accomplishments in professional sports give him a unique perspective on health and athletics making him a valued asset to the accelmed team   executives network accelmed enjoys close collaboration with a network of seasoned executives who have built led and sold companies for billions of dollars these executives assist accelmed in identifying and analyzing potential opportunities and may serve in key leadership roles in future platform companies             the portfolio reflects a diversity of strategies employed in accelmed’s first and second funds   platforms  cogentix   cogentix nasdaqcgnt is a us based global urology focused company its main areas of activity are in overactive bladder oab advanced endoscopy systems and urethral bulking agents  httpwwwcogentixmedicalcom    endochoice sold   a global platformtechnology company focused on gastrointestinal gi endoscopy endochoice has merged with peer medical an israeli company which developed of a unique endoscopy technology to form a leading player in the gi industry endochoice is headquartered in alpharetta georgia with its rd center based in israel endochoice completed a successful ipo in june  and was sold to boston scientific in october  httpwwwendochoicecom  ophthalmic imaging systems sold   ophthalmic imaging systems ois is a leading provider of ophthalmic imaging and informatics solutions ois was the first investment of accelmed closed q and was sold two years later q to merge healthcare nasdaq merge httpwwwcanadianpharmacynet” target”blank”httpwwwcanadianpharmacynet  volcano sold   through its multimodality platform volcano corporation nasdaq volc is the global leader in intravascular imaging for coronary peripheral and physiology applications accelmed took a role of an active investor in the company which contributed to a successful acquisition by philips only a few months later httpwwwvolcanocorpcom   targeted innovation  corvia   corvia is developing the first transcatheter device to treat congestive heart failure chf the company’s innovative iasd™ interatrial shunt device system is designed to relieve increased left atrial pressure httpcorviamedicalcom  valcare medical   valcare medical was founded in  and is dedicated to designing developing and commercializing devices and accessories for minimally invasive treatment of heart valve disease httpwwwvalcaremedicalcom  digma   digma medical is an exciting new medical device startup that is focused on developing innovative solutions to metabolic diseases  sonivie   sonivie is developing an advanced denervation solution to treat pulmonary hypertension   incubator  eximo medical   eximo medical ltd is an early stage startup company founded in  the company is developing a novel medical device based on a single use hybrid catheter for various medical applications that require precise and safe material removal these applications have substantial and growing markets httpwwweximomedicalcom  memic   memic innovative surgery ltd is an early stage robotic company that develops an innovative surgical robot the surgical robot is based on a novel design which enables intuitive control and a new surgical approach for laparoscopic procedures  nitinotes   nitinotes is developing advanced nonsurgical bariatric solutions  revamp   revamp is offering an innovative temporary catheter for acute heart failure ahf primarily targeting diuretic resistance patients   venture capital  cartiheal   cartiheal is the developer of proprietary biocompatible and biodegradable offtheshelf implants for cartilage and bone regeneration cartiheal’s acellular implant is arthroscopically pressfit within a cartilage or osteochondral defect in a singlestage procedure and supports vessels formation followed by rapid invasion and adhesion of bone marrow mesenchymal stem cells the ce marked implant has significant loadbearing capability allowing patients faster rehabilitation httpwwwcartihealcom  endospan   endospan ltd is a vcbacked clinicalstage medical device startup developing a novel endovascular system intended to provide the next generation in endovascular aortic aneurysm repair evar endospan’s system aims to achieve a much smaller crossing profile compared with contemporary devices the system is intended for unilateral and purely percutaneous approach thus simplifying and significantly shortening the procedure httpwwwendospancom  nitiloop   nitiloop is dedicated to the development of cutting edge vascular support microcatheters our technology provides superior operatorcontrolled positioning and support in multiple applications nitiloop brings to the market ‘first choice’ products to overcome difficult lesions httpwwwnitiloopcom  picardia   picardia ltd is a medical device startup company developing a novel low profile catheter for the treatment of aortic stenosis the company’s proprietary technology is based on delivering mechanical impact for creating fractures in valve calcifications without injuring the surrounding soft tissue this treatment which only takes several seconds is intended to increase the valve effective orifice area without the need to replace the valve httpwwwpicardiacom   contact us office  madison avenue suite b new york ny  tel 0 israel office  hachoshlim st th floor herzliya pituach  tel  email infoaccelmedcom   accelmed growth partners agp ltd  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors accelmed growth partners agp ltd check out list of companies and businesses related to accelmed growth partners agp ltd find out accelmed growth partners agp ltd address and contact details view other people related to accelmed growth partners agp ltd  coworkers colleagues companions etc address  hachochlim street th floor herzliya pituach  israel companies related to accelmed growth partners agp ltd cikcompany namepositioncompany addresscogentix medical inc de feltl road minnetonka  accelmed growth partners agp ltd on the web persons related to accelmed growth partners agp ltd  cogentix medical inc denamepositioncityaccelmed growth partners gp lpherzliya pituachaccelmed growth partners lpherzliya pituachaccelmed growth partners management ltdherzliya pituachdavid w andersondirector montgomeryvilledavid w andersondirector montgomerydavid w andersondirector orangeburgdavid w andersondirector montgomeryvillecynthia f ansaripresident and ceo orangeburgkenneth w ansteydirector natickkenneth w ansteydirector orangeburgkenneth w ansteydirector orangeburgkenneth w ansteyminneapoliscarlos babinifremontcarlos babinieastonwarren l bielkedirector eden prairiewarren l bielkedirector orangeburgwarren l bielkeinterim ceo eden prariepolsky bruceorangeburgyoav m cohenchief financial officer orangeburgjames a dortadirector minnetonkakeith j c darraghvice president finance orangeburganderson davidorangeburggerald d erbvp marketing  sales fishersuri geigerherzeliaron hadanichief executive officer teaneckron hadanichief executive officer teaneckron hadanichief executive officer orangeburgron hadaniteaneckdarin hammersceo minnetonkadavid hanukaorangeburgdavid hanukavp research and development orangeburggideon hirschmannorangeburggideon hirschmann orangeburggideon hirschmannvice president of operations orangeburggideon hirschmannorangeburgrydzewski johnorangeburgwolf katherineorangeburgoneda katsumiorangeburgrobert killchairman president and ceo minnetonkalothar koobdirector peabodylothar kooborangeburglothar koobdirector orangeburgmark s landmanvp operations medical segment sharonmark s landmanvp disposables operations orangeburgmark s landmanvice president pell lewisorangeburgkoob lotharorangeburgthomas m olmsteadvp sales medical segment university heightskatsumi onedachairman of bod alpinekatsumi onedadirector orangeburgkatsumi onedadirector jitendra patelvp sales industrial segment norwoodjitendra patelvp industrial division orangeburgjitendra patelvp sales industrial segment kenneth h paulusdirector minnetonkacheryl pegusdirector orangeburglewis c pelldirector naticklewis c pellvicechairman of bod orangeburglewis c pelldirector orangeburglewis c pelldirector natickbruce polskyorangeburgbruce polskydirector orangeburgbrett reynoldssvp cfo treasurer st paulkevin h rochedirector minnetonkajohn j rydzewskiorangeburgjohn j rydzewskidirector costa mesajohn j rydzewskidirector orangeburgkenneth a sametdirector rockvillenachum shamirdirector austingary siegelvp finance orangeburgkenneth a spectorvp rd framinghamjames p staunerdirector lake forestjames a tracycfo newtonuroplasty incminnetonkajohn j wallacedirector walthamjohn j wallacedirector walthamjohn j wallacedirector cantonjohn j wallacedirector orangeburgjohn j wallacebielke warrenorangeburgsven wehrweindirector minneapoliskatherine wolforangeburgkatherine wolfexec vp corp dev  cfo orangeburgkatherine wolfexec vp corp dev  cfo orangeburghoward i zaubermandirector orangeburg   accelmed growth partners lp top holdings whalewisdom search all search f filers only search sec filer search stocks only search mgmt inv cos only etfs only search active accelmed growth partners lp • herzliya pituach l • private equity how do i update this listing accelmed growth partners is based out of herzliya pituach whalewisdom has at least  dg filings in our database for accelmed growth partners the firm last filed a form d notice of exempt offering of securities on 0 the filing was for a pooled investment fund private equity fund the notice included securities offered of pooled investment fund interests summary dg insider form  form d  create email alert × email notification log in or signup to see more advanced email alert options such as selecting any type of sec form multiple filers or classes of filers and much more or to simply have an email sent to you whenever we receive a new f filing from accelmed growth partners lp enter your email address below and choose submit your email cancel contact info accelmed growth partners lp  hachoshlim street th floor herzliya pituach l    0 business phone  recent sec filings da filed on 0  filed on 0 sc d filed on 0 da filed on 0 d filed on 00 current dg holdings stock sector shares held market value rank source source date cogentix medical cgnt health care 0   d 0 schedule d and g events since 0 subscription required form   nonderivative insider transactions since 0 loading form d filings form d is a form to be used to file a notice of an exempt offering of securities with the securities and exchange commission form d contains basic information about the offering and the company form d filings filing date form type industry group securities offered total offering amount total amount sold total remaining 0 da pooled investment fund private equity fund pooled investment fund interests    0 da pooled investment fund private equity fund pooled investment fund interests    00 d pooled investment fund private equity fund pooled investment fund interests  0  other issuers in filings name address no other issuers related parties included in filings name address relationship agp ltd general partner of the gp accelmed growth partners subscription required promoter gp lp general partner accelmed growth partners subscription required promoter moshe arkin subscription required director uri geiger subscription required director elevate your investments try it for free agp ltd general accelmed growth partnerss involvement in venture capital via accelmed growth partners lp want to see morewant to find out who got funded and who’s funding the next big thing in real time all across the world tailored to your specific areas of focus deals per dayget access to the most exhaustive worldwide funding watch on the webcomprehensive funding informationknow about who invested in a company which sites covered the event the funding history etcexclusive insightsview original analytics such as most dynamic industries most active investors and morestay awareget emailed when deals critical to your business happen filter by region industry and topics of interestas seen onhave a loginsign inregister nowits freeuse your social accountor fill in the quick formregister nowpromise we wont spamsign invia your social accountvia your existing wgf accountremember meregister its freeforgot your passwordsign inforgot your passwordenter your email and we will send you your new passwordreset passwordthe worlds largest funding basepeopleagpltdgeneralaccelmedgrowthpartnerssectionpeoplesubsectiondetailid search deals by company name industry location investors search agp ltd generalaccelmed growth partnersget alertedif agp ltd general accelmed growth partners gets fundedagp ltd general accelmed growth partnersaccelmed growth partners lp  promoterdeals involving agp ltd general accelmed growth partners raised with accelmed growth partners lp on march 0 raised with accelmed growth partners lp on january please note that all data is automatically extracted and errors can occurthe whogotfunded team has not necessarily reviewed the information in this page and has not determined if it is accurate and completesome of the profile information was collected using the crunchbase api for more details on the profile please check agp ltd general  on crunchbaseinaccurate data help us improve whogotfunded post a comment accelmed growth partners lp  who is raising money  sec filings of fundraisings and investments in hedge funds startups and private equity companies who is raising money accelmed growth partners lp funding details accelmed growth partners lp industry pooled investment fundcik number address  hachoshlim street th floor herzliya pituach 0phone number  latest news accelmed growth partners lp raised  from  investors on 0 accelmed growth partners lp filings datefiling typeofferedsoldremainingmin investmentinvest countexemption  exlusions 0amended form d00b c csec filing0amended form d00b c csec filing00new form d00b c csec filing accelmed growth partners lp raised  in total directors and executives of accelmed growth partners lp key people in accelmed growth partners lp uri geigermoshe arkingp lp accelmed growth partnersagp ltd general accelmed growth partners last visited companies rentar environmental solutions inc riskiq inc rockwater energy solutions inc shr capital partners llc slam opportunity fund lp  whoisraisingmoneycom daily updated news about investment into startups hedge funds and private equity companies accelmed growth partners lp  pooled investment fund accelmed growth partners formdscom  sec filings of fundraisings and investments in hedge funds private equity firms startups and growing companies formdscom newest filter local accelmed growth partners lp industry pooled investment fund see others in industry address  hachoshlim street  th floor herzliya pituach l 0phone  filings date filingtype reported sold incremental cash type exemptions link to raw filing 0 amended   other 0b c c sec link 0 amended  0 other 0b c c sec link 00 new 0 0 other 0b c c sec link directors and executives current and past name role gp lp general partner accelmed growth partners promoter agp ltd general partner of the gp accelmed growth partners promoter moshe arkin director uri geiger director eximo medical an accelmed portfolio company announces the successful completion of a multicenter eximo medical an accelmed portfolio company announces the successful completion of a multicenter firstinhuman trial in europe with a hybrid catheter for treating complex lesions in peripheral blood vessels next generation novel hybrid laser  mechanical system provides a safe solution for more than  million patients in the united states  a market of over  billion apr 0  0 et from accelmed rehovot israel april   prnewswire  eximo medical a medical device company that is developing a laser system and unique catheters for the treatment of peripheral artery disease pad has successfully completed a multicenter clinical trial for the purpose of obtaining ce approval for marketing in europe the results of the trial indicate that use of the eximo system provides a safe precise and highly efficacious solution in cases of partial blockage complete blockage and severe calcification the trial which was led by two physicians from poland included  patients some of whom required bypass surgery or leg amputation and are no longer at risk of amputation following the treatment eximo was founded by accelmed a medical device investment fund in  in july  eximo completed its round a investment led by accelmed following the success of the trial the company is now pursuing ce mark and will be looking to receive fda approval in  the eximo system is based on a solidstate ultraviolet laser with a wavelength of  nm the system is connected to a hybrid catheter which combines tissue ablation by means of the laser and resection with a blunt mechanical blade eximo is the first company in the world to have succeeded in actively combining a  nm laser with a mechanical blade in a way that enables a high level of accuracy in cutting through vascular blockages eximos proprietary hybrid lasermechanical blade design removes blockages irrespective of the type of blockage or the size of the blood vessel and increases the efficacy and safety of performance while reducing the risk of puncturing the blood vessel compared to competing technologies vascular blockage of the lower extremities is the main cause of  of limb amputations in the united states approximately  amputations per year with an estimated total cost of  billion to the us health system treatment with the system developed by eximo will enable the blockage to be efficiently and safely eliminated saving many patients from limb amputations today there are over  million pad patients in the united states and the market size is estimated to be in excess of  billion dr waclaw kuczmik senior surgeon at the medical university of silesia in katowice poland stated we are proud to be the first medical center in the world to have treated patients with the eximo system the treatment of all  patients by us was highly successful without any complications all of the patients have experienced significant pain relief in the treated limb and significant improvement in quality of life yoel zabar ceo of eximo stated we are pleased to announce the successful completion of a firstinhuman study with a pad application which constitutes a significant milestone that will enable the receipt of ce marketing approval in europe we are proud that thanks to the unique technology developed by our company we were able to alleviate patients suffering and prevent complicated unnecessary surgeries which could in extreme cases even have led to amputation of the leg the completion of the trial represents an additional significant step toward a multiparticipant fda trial in the united states  a potential market of billions of dollars about eximo  eximo medical ltd which is located in rehovot is an israeli company that was founded in  by accelmed the company is devoted to developing efficacious and safe solutions for the treatment of vascular blockages the companys catheters are based on an innovative hybrid technology which includes a combination of a compact laser system and mechanical elements eximos future products include solutions for the removal of pacemaker electrodes le  lead extraction in cases of damage to the electrode or infection and at a later stage catheters for procedures in the digestive tract in march  eximo won the innovative company award at the idss electrophysiology conference the founders of the company and a scientific consulting committee which includes renowned specialists from american and israeli medical institutes support the eximo medical management team additional information is available on the companys website httpwwweximomedicalcom about accelmed accelmed is the largest pure play medical device fund in israel accelmed focuses on global investments in mature companies that might serve as a platform to israeli companies and also builds companies that develop innovative medical devices solutions for major markets  such as diabetes obesity and heart diseases  in which there is currently no medical solution since it was founded in  by mori arkin the chairman of the investment committee and dr uri geiger the managing partner accelmed has made  investments in medical device companies including ma and ipo of five of them accelmed manages over  million invested in medical device and has recently announced initial closing for its third fund accelmed growth partners  agp existing companies in the portfolio include corvia valcare endospan sonivie cartiheal nitiloop digma memic and nitinotes accelmed has a large and experienced investment management team which other than dr uri geiger and mori arkin includes four additional partners dr irit yaniv ilan ben oren lior shav and amir blatt together with a team of analysts and wellknown advisors more information can be found on accelmeds website httpwwwaccelmedcom for more information   meirav bauer km investor relations ltd tel  meiravbkmircoil httpwwwkmircoil source accelmed view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more jun    et preview valcare medical an accelmed portfolio company announces successful firstinhuman procedures of the amend™ catheter delivered annuloplasty ring mar   0 et preview sonivie a portfolio company of accelmed fund announces successful completion of firstinhuman procedures using the tivus catheter my news release contains wide tables view fullscreen looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search valcare medical an accelmed portfolio company announces successful firstinhuman procedures of the amend™ catheter delivered annuloplasty ring  the business journals menu select a city national albany albuquerque atlanta austin baltimore birmingham boston buffalo charlotte chicago cincinnati columbus dallas dayton denver greensborowinstonsalem honolulu houston jacksonville kansas city los angeles louisville memphis miamifort lauderdale milwaukee minneapolisst paul nashville new york orlando philadelphia phoenix pittsburgh portland raleighdurham sacramento san antonio san francisco seattle silicon valley st louis tampa bay washington dc wichita limited time offer subscribe now search × close sign in sign in your account your account welcome your account sign in existing users create your free account dont have an account your account subscriptions newsletters custom notifications my custom site manage site users sign out sign in sign in your account search home industries  topics all industries  topics banking  financial services career  workplace commercial real estate education energy food  lifestyle government  regulations health care manufacturing media  marketing philanthropy  nonprofits professional services residential real estate retailing sports business technology transportation travel  tourism sponsored content cre now we value your business office environments small business marketing know your neighborhood news news latest news business pulse press releases lists  awards lists all lists build your own lists people  companies companies top private companies find businesses for sale search for company news people people on the move contact top executives executive profiles search for people in the news events events business event calendar nominations more… jobs find or post a job store subscriptions reprints  more how to grow your business advance your career thought leadership trends tips and insights from our partners subscribers manage your account about  contact about the business journals advertise help  faqs call center directory apps  syndication newsletters acbj publications bizwomen upstart hemmings sports business journal inside lacrosse bostinno dcinno chicagoinno austininno select a city national albany albuquerque atlanta austin baltimore birmingham boston buffalo charlotte chicago cincinnati columbus dallas dayton denver greensborowinstonsalem honolulu houston jacksonville kansas city los angeles louisville memphis miamifort lauderdale milwaukee minneapolisst paul nashville new york orlando philadelphia phoenix pittsburgh portland raleighdurham sacramento san antonio san francisco seattle silicon valley st louis tampa bay washington dc wichita follow us twitter linkedin facebook google  press releases valcare medical an accelmed portfolio company announces successful firstinhuman procedures of the amend™ catheter delivered annuloplasty ring jun   am edt herzliya israel june   prnewswire  novel semirigid d shaped ring provides a minimally invasive solution for mitral valve regurgitation  a market of over  billion in the us alone expands management team with appointment of mr shuki porath as ceo to lead clinical development and commercialization to current and new markets valcare medical an accelmed portfolio company the developer of novel medical devices for minimally invasive treatment of mitral valve regurgitation announced today the successful completion of first phase of the its firstinhuman fih multicenter clinical trial taking place in israel and europe valcare developed the amend™ mitral valve repair annuloplasty ring a semirigid a d shaped ring that emulates the current gold standard for patients who suffer from mitral valve regurgitation the valve that controls blood flow between the left atrium and left ventricle in a series of cases the ring was successfully trans apically delivered through an advanced catheterbased delivery system and was secured to the annulus by a series of novel integral anchors the procedure was performed on a high surgical risk patient in a minimallyinvasive transapical approach and in a relatively short time stated prof amit segev director cardiac catheterization services at the heart center at sheba medical center israel and prof ehud raanani head of the cardiothoracic surgery department who performed one of the procedures using the valcare system we were able to repair the patients mitral valve and significantly reduce valvular incompetence reducing mr from sever  to trace  we are excited to be one the first centers in the world to use this novel technology to help our patients additionally valcares amend™ system was implanted successfully by the heart team at shaare zedek medical center interventional cardiology laboratories in jerusalem dr almagor  dr mirkeen and in a compassionate care procedure performed in april by professor gino gerosa and dr andrea colli cardiac surgeons from the padova university hospital in italy alongside the clinical progress the company announced the expansion of its management team and the appointment of mr shuki porath as ceo mr shuki porath has over  years of medical device senior managerial experience including product management business development commercialization and clinical applications prior to joining valcare medical mr porath served as president  ceo at keystone heart and as senior executive at biosense webster a johnson  johnson company mr porath holds a bsc in electrical engineering msc and mba  all from the technion israel institute of technology sam shaolian the founder of valcare and inventor of the technology will become the cto of the company and continue to lead the future products of the company uri geiger managing partner of accelmed and valcares chairman of the board commented we are excited with the successful completion of the first implantations of the amend™ system and thrilled to welcome shuki porath to valcare leading its clinical development and commercialization to current and new markets valcares novel technology is a pioneering breakthrough for the treatment of mitral valve regurgitation and could be a base for additional modalities for treatment of other valve disorders the team is currently focusing on adapting the delivery technique to a transeptal approach allowing for deployment of the system through a puncture in the groin as well as using the system to treat tricuspid incompetence another extremely common problem in addition we have explored this novel technology using the ring as a landing zone to support a mitral valve prosthesis in preclinical studies generating interest from a number of other companies active in this arena as this provides another opportunity to treat patients with conditions that may be more suitable for heart valve replacement than repair the amend™ system is expected to address the  billion market  billion in the us alone for medical devices geared towards minimally invasive treatment of mitral valve disease a recently granted us patent on the valve in ring enables valcare to use the amend™ device also for the replacement of the mitral valve and for tricuspid vale repair about valcare medical  valcare medical based in herzliya pituach israel develops advanced medical implants and delivery systems for the treatment of heart valve regurgitation in a minimally invasive manner the valcare amend™ system is the first device aimed for treatment of mitral valve regurgitation and currently under clinical study by the company valcare medical was founded in  by accelmed fund as part of its targeted innovation model accelmed and valcare medicals founder and cto samuel shaolian established the company based on technology spanned off micardia corporation to leverage the expertise and experience of the leading technical and clinical experts in the field of heart surgery and cardiology to develop break though technologies for patients suffering from heart disease for more information refer to httpwwwvalcaremedicalcom about accelmed accelmed is the largest pure play medical device fund in israel accelmed focuses on global investments in mature companies that might serve as a platform to israeli companies and also builds companies that develop innovative medical device solutions for major markets  such as diabetes obesity and heart diseases  in which there is currently no medical solution since it was founded in  by mori arkin the chairman of the investment committee and dr uri geiger the managing partner accelmed has made  investments in medical device companies including ma and ipo of five of them accelmed manages over  million invested in medical device and has announced initial closing for its third fund accelmed growth partners  agp existing companies in the portfolio include corvia valcare endospan sonivie cartiheal nitiloop digma memic and nitinotes accelmed has a large and experienced investment management team in the medical device field which other than dr uri geiger and mori arkin includes four additional partners dr irit yaniv ilan ben oren lior shav and amir blatt together with a team of analysts and wellknown advisors more information can be found on accelmeds website httpwwwaccelmedcom for more information meirav bauer km investor relations tel  meiravbkmircoil httpwwwkmircoil source accelmed the information on this page is provided by pr newswire all rights reserved reproduction or redistribution of this content without prior written consent from pr newswire is strictly prohibited is not responsible for this content learn more about this service about pr newswire the information on this page is provided by pr newswire the business journals is not responsible for this content learn more eximo medical an accelmed portfolio company announces the successful completion of a multi center first in human trial in europe with a hybrid catheter employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km0  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       eximo medical an accelmed portfolio company announces the successful completion of a multicenter firstinhuman trial in europe with a hybrid catheter for treating complex lesions in peripheral blood vessels tweet  0 am   life sciences jobs     bullet newest jobs  last  hours   bullet california jobs   bullet massachusetts jobs   bullet new jersey jobs   bullet maryland jobs   bullet washington jobs   view more jobs next generation novel hybrid laser  mechanical system provides a safe solution for more than  million patients in the united states  a market of over  billion rehovot israel april   prnewswire  eximo medical a medical device company that is developing a laser system and unique catheters for the treatment of peripheral artery disease pad has successfully completed a multicenter clinical trial for the purpose of obtaining ce approval for marketing in europe the results of the trial indicate that use of the eximo system provides a safe precise and highly efficacious solution in cases of partial blockage complete blockage and severe calcification the trial which was led by two physicians from poland included  patients some of whom required bypass surgery or leg amputation and are no longer at risk of amputation following the treatment eximo was founded by accelmed a medical device investment fund in  in july  eximo completed its round a investment led by accelmed following the success of the trial the company is now pursuing ce mark and will be looking to receive fda approval in  the eximo system is based on a solidstate ultraviolet laser with a wavelength of  nm the system is connected to a hybrid catheter which combines tissue ablation by means of the laser and resection with a blunt mechanical blade eximo is the first company in the world to have succeeded in actively combining a  nm laser with a mechanical blade in a way that enables a high level of accuracy in cutting through vascular blockages eximos proprietary hybrid lasermechanical blade design removes blockages irrespective of the type of blockage or the size of the blood vessel and increases the efficacy and safety of performance while reducing the risk of puncturing the blood vessel compared to competing technologies vascular blockage of the lower extremities is the main cause of  of limb amputations in the united states approximately  amputations per year with an estimated total cost of  billion to the us health system treatment with the system developed by eximo will enable the blockage to be efficiently and safely eliminated saving many patients from limb amputations today there are over  million pad patients in the united states and the market size is estimated to be in excess of  billion dr waclaw kuczmik senior surgeon at the medical university of silesia in katowice poland stated we are proud to be the first medical center in the world to have treated patients with the eximo system the treatment of all  patients by us was highly successful without any complications all of the patients have experienced significant pain relief in the treated limb and significant improvement in quality of life yoel zabar ceo of eximo stated we are pleased to announce the successful completion of a firstinhuman study with a pad application which constitutes a significant milestone that will enable the receipt of ce marketing approval in europe we are proud that thanks to the unique technology developed by our company we were able to alleviate patients suffering and prevent complicated unnecessary surgeries which could in extreme cases even have led to amputation of the leg the completion of the trial represents an additional significant step toward a multiparticipant fda trial in the united states  a potential market of billions of dollars about eximo eximo medical ltd which is located in rehovot is an israeli company that was founded in  by accelmed the company is devoted to developing efficacious and safe solutions for the treatment of vascular blockages the companys catheters are based on an innovative hybrid technology which includes a combination of a compact laser system and mechanical elements eximos future products include solutions for the removal of pacemaker electrodes le  lead extraction in cases of damage to the electrode or infection and at a later stage catheters for procedures in the digestive tract in march  eximo won the innovative company award at the idss electrophysiology conference the founders of the company and a scientific consulting committee which includes renowned specialists from american and israeli medical institutes support the eximo medical management team additional information is available on the companys website httpwwweximomedicalcom about accelmed accelmed is the largest pure play medical device fund in israel accelmed focuses on global investments in mature companies that might serve as a platform to israeli companies and also builds companies that develop innovative medical devices solutions for major markets  such as diabetes obesity and heart diseases  in which there is currently no medical solution since it was founded in  by mori arkin the chairman of the investment committee and dr uri geiger the managing partner accelmed has made  investments in medical device companies including ma and ipo of five of them accelmed manages over  million invested in medical device and has recently announced initial closing for its third fund accelmed growth partners  agp existing companies in the portfolio include corvia valcare endospan sonivie cartiheal nitiloop digma memic and nitinotes accelmed has a large and experienced investment management team which other than dr uri geiger and mori arkin includes four additional partners dr irit yaniv ilan ben oren lior shav and amir blatt together with a team of analysts and wellknown advisors more information can be found on accelmeds website httpwwwaccelmedcom for more information meirav bauer km investor relations ltd tel  meiravbkmircoil httpwwwkmircoil read at biospacecom related news  awesome biotechs to know in paris sec fines and bans once prominent bay area investor steven burrill over stolen investor funds genetically engineered pig hearts survive a recordbreaking two years inside baboons national heart lung and blood institute study spotlight on immigrant life science company leaders in massachusetts theranos hit again as new study shows firms tests arent as reliable as standard tests nonhormonal male birth control proves effective in early study university of illinois reveals dozens of startups are chasing the cancer blood test dream as flailing valeant vrx pushes back earnings deadlines bausch  lomb sale potentially on the table socal biotech trovagene trovs stock tanks after firing ceo cfo top talent leaving google googs verily googl after working with divisive and compulsive leader ceo andrew conrad please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • eximo medical ltd   • medical devices • medical dev  diag  research